Show simple item record

dc.contributor.authorLong, G. V.
dc.contributor.authorArance, A.
dc.contributor.authorMortier, L.
dc.contributor.authorLorigan, Paul C
dc.contributor.authorBlank, C.
dc.contributor.authorMohr, P.
dc.contributor.authorSchachter, J.
dc.contributor.authorGrob, J. J.
dc.contributor.authorLotem, M.
dc.contributor.authorMiddleton, M. R.
dc.contributor.authorNeyns, B.
dc.contributor.authorSteven, N.
dc.contributor.authorRibas, A.
dc.contributor.authorWalpole, E.
dc.contributor.authorCarlino, M. S.
dc.contributor.authorLebbe, C.
dc.contributor.authorSznol, M.
dc.contributor.authorJensen, E.
dc.contributor.authorLeiby, M. A.
dc.contributor.authorIbrahim, N.
dc.contributor.authorRobert, C.
dc.date.accessioned2021-11-26T10:04:38Z
dc.date.available2021-11-26T10:04:38Z
dc.date.issued2021en
dc.identifier.citationLong GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, et al. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006 [Internet]. Annals of Oncology. Elsevier BV; 2021.en
dc.identifier.pmid34710571en
dc.identifier.doi10.1016/j.annonc.2021.10.010en
dc.identifier.urihttp://hdl.handle.net/10541/624765
dc.description.abstractBackground: Antitumor activity of ipilimumab or BRAF ± MEK inhibition (BRAFi ± MEKi) following pembrolizumab in melanoma is poorly characterized. Patients and methods: In the phase 3 KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab 10 mg/kg once every 2 or 3 weeks (Q3W) or ipilimumab 3 mg/kg Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy after pembrolizumab and includes patients who completed or discontinued pembrolizumab after ≥1 dose. Pembrolizumab arms were pooled. Results: At data cutoff (December 4, 2017), median follow-up was 46.9 months. Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi ± MEKi for 59 (10.6%) (33 received BRAFi + MEKi, 26 BRAFi alone; 37 [62.7%] were BRAFi ± MEKi-naïve). In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% (1 complete response [CR]; 17 partial response [PR]); 79.6% had discontinued pembrolizumab due to progressive disease (PD); median OS was 21.5 months. ORR with subsequent ipilimumab was 15.5%; 11/16 responses (8 CRs; 3 PRs) were ongoing. ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab. Median OS from ipilimumab initiation was 9.8 months. In the subsequent BRAFi ± MEKi group, ORR with previous pembrolizumab was 13.5% (8 PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months. ORR with subsequent BRAFi ± MEKi was 30.5%, 7/18 responses (4 CR, 3 PR) were ongoing. Median OS from BRAFi ± MEKi initiation was 12.9 months. ORR for BRAFi ± MEKi-naïve patients who received subsequent BRAFi ± MEKi was 43.2%; 6/16 were ongoing (3 CR, 3 PR). Conclusions: Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2021.10.010en
dc.titleAntitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab in patients with advanced melanoma: analysis from KEYNOTE-006en
dc.typeArticleen
dc.contributor.departmentMelanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, NSW, Australiaen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record